Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039586 | 0.97 | GAA (0.54) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL4363535 | 0.95 | — | — | |
| SCHEMBL17092622 | 0.86 | GAA (0.56) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL10892602 | 0.83 | GAA (0.54) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL142180 | 0.83 | GAA (0.61) | GAAALDH1A1POLBMAPTHTT | |
| Hydrochloric Acid SCHEMBL11699100 | 0.81 | GAA (0.58) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL4367538 | 0.79 | GAA (0.50) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL6039364 | 0.78 | ALDH1A1 (0.50) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL8809555 | 0.77 | GAA (0.48) | GAAALDH1A1POLBMAPTHTT | |
| SCHEMBL1306310 | 0.77 | GAA (0.48) | GAAALDH1A1POLBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| WO-2006038001-A1 | AMINOPYRIMIDINE DERIVATIVES AS JNK INHIBITORS | CELLTECH R & D LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | GAA 2017/4885ALDH1A1 3317/4885POLB 1028/4885 |
| US-20050101630-A1 | 4-Substituted quinolines as antitumor agents | NQO2, TPD52L2, MLX | GAA 1185/4885ALDH1A1 2334/4885POLB 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.